Columbus McKinnon (CMCO) Prices 3.75M Share Upsized Common Offering at $48/Sh

Pre-Open Stock Movers 04/29: (VER) (OSTK) (FB) Higher; (ADVM) (CTXS) (EBAY) Lower (more...)

Today's Pre-Open Stock Movers:

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.

Galera Therapeutics, Inc. (Nasdaq:... More

After-Hours Stock Movers 04/28: (GRTX) (AZPN) (CAKE) Higher; (ADVM) (CMCO) (HOLX) Lower (more...)

Today's After-Hours Movers:

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.

Galera Therapeutics, Inc. (Nasdaq:... More

Columbus McKinnon (CMCO) Announces Commencement of Common Stock Offering

Columbus McKinnon Corporation (Nasdaq: CMCO) (the Company or Columbus McKinnon), a leading designer and manufacturer of intelligent motion solutions for material handling, today announced that it has commenced an underwritten public offering, subject to market and other conditions, of $150.0 million of its common stock. The... More